Solvonis Therapeutics PLC

SVNS · Main Market · Health Care · mcap £8.3m · 0.1p

Beta Briefing, track record and signals & risks are not ready for Solvonis Therapeutics PLC yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 61 companies are already wired into a briefing: browse them.

Financials · LTM to 30 Jun 26

Source: results 30 Sep 26 ↗

Revenue: –
Operating profit: –
Net income: −£5.7m
Free cash flow: −£3.3m
Net cash: £659k
Market cap: £8.3m
EV / EBIT: –
FCF yield: −40.1%
Price / book: 1.7×

Latest half-year · H1 26 vs H1 25 results 30 Sep 26 ↗

Cash from operations: −£1.1m

Extracted automatically from the company's results announcements; check the source before relying on a figure. Not investment advice.

Key figures As reported

Income statement Balance sheet Cash flow

Annual Half-yearly

Standardised line items in £m, comparable across companies; when a later report restated a period, the later figure is shown and marked ^r (hover for the figure first reported). Italic = calculated (LTM, H2 = FY − H1); a year of other than 12 months is marked (15m). Hover a value for its source.

Latest report: H1 26 (six months to 30 Jun 26), published 30 Sep 26 · read the results ↗

Source ↗

	June 2026 £'000	Jun 2025 £'000
Cash flow from operating activities
Loss before tax	(1,437)	(1,621)
Adjustments for
Finance expenses	-	4
Share based payments	26	193
Foreign exchange movements	2	(96)
Changes in working capital
Decrease in trade and other receivables	97	5
Increase in trade and other payables	245	501
Net cash outflow from operating activities	(1,067)	(1,014)
Cash flow from investing activities
Cash acquired on acquisition of subsidiary	-	8
Net cash inflow from investing activities	-	8
Cash flows from financing activities
Proceeds from issue of shares	-	2,000
Share Issue Costs	-	(29)
Net cash inflow from financing activities	-	1,971
Net (decrease)/increase in cash and cash equivalents	(1,067)	965
Cash and cash equivalents at beginning of period	1,720	757
Foreign exchange impact on cash	6	(3)
Cash and cash equivalents at the end of the period	659	1,719

Source ↗

	2025 £'000	2024 £'000
NON-CURRENT ASSETS
Intangibles	5,667	2,088
Other non-current assets	-	300
TOTAL NON-CURRENT ASSETS	5,667	2,388
CURRENT ASSETS
Cash and cash equivalents	1,720	757
Trade and other receivables	198	58
TOTAL CURRENT ASSETS	1,918	815
TOTAL ASSETS	7,585	3,203
NON-CURRENT LIABILITIES
Borrowings	75	-
Trade and other payables	839	-
TOTAL NON-CURRENT LIABILITIES	914	-
CURRENT LIABILITIES
Trade and other payables	480	119
TOTAL CURRENT LIABILITIES	480	119
TOTAL LIABILITIES	1,394	119
NET ASSETS	6,191	3,084
EQUITY
Share capital	6,743	2,233
Share premium	10,870	7,362
Capital reduction reserve	2,500	2,500
Share based payments reserve	2,543	1,544
Foreign exchange reserve	(170)	-
Retained earnings	(16,295)	(10,555)
TOTAL EQUITY	6,191	3,084

Source ↗

	2025 £'000	2024 £'000
Cash flow from operating activities
Loss for the financial year	(5,740)	(1,590)
Adjustments for
Share based payments	559	317
Settlement of fees through issue of equity	365	231
Impairment of intangible assets	2,263	-
Gain on deconsolidation	-	(125)
Finance expenses	-	64
Foreign exchange movements	(131)	-
Changes in working capital
(Increase) / decrease in trade and other receivables	(88)	31
(Decrease) in trade and other payables	(501)	(58)
Net cash outflow from operating activities	(3,273)	(1,130)
Cash flows from investing activities
Investment in non-current asset	-	(320)
Repayments on right-of-use assets	-	(4)
Disposal of subsidiary, net of cash disposed	-	(13)
Net cash flow from investing activities	-	(337)
Cash flows from financing activities
Proceeds from issue of shares	4,270	1,924
Share Issue Costs	(39)	(41)
Proceeds from issue of convertible notes	-	200
Net cash flow from financing activities	4,231	2,083
Net increase in cash and cash equivalents	958	616
Cash and cash equivalents at beginning of the period	757	155
Foreign exchange effect on cash balance	5	(14)
Cash and cash equivalents at end of the period	1,720	757

	LTM Jun 26	FY 25	FY 24
Revenue to operating profit
Share-based payments	0.4	0.6	0.3
Operating profit to net income
Net income (owners)	–	(5.7)	(1.6)

	H1 26	vs H1 25	H2 25	H1 25
Revenue to operating profit
Share-based payments	0.0	−87%	0.4	0.2
Operating profit to net income
Profit before tax	(1.4)	n/m	–	(1.6)

	LTM Jun 26	FY 25	FY 24
Operating activities
Cash from operations	(3.3)	(3.3)	(1.1)
Financing activities
Shares issued	2.3	4.3	1.9

	H1 26	vs H1 25	H2 25	H1 25
Operating activities
Cash from operations	(1.1)	n/m	(2.3)	(1.0)
Financing activities
Shares issued	0.0	n/m	2.3	2.0

	30 Jun 26	31 Dec 25	31 Dec 24
Non-current assets
Goodwill	–	5.7	2.1
Non-current assets	–	5.7	2.4
Current assets
Trade receivables	–	0.2	0.1
Cash	0.7	1.7	0.8
Current assets	–	1.9	0.8
Total assets	6.4	7.6	3.2
Current liabilities
Trade payables	–	0.5	0.1
Current liabilities	–	0.5	0.1
Non-current liabilities
Borrowings, non-current	–	0.1	–
Non-current liabilities	–	0.9	0.0
Total liabilities	–	1.4	0.1
Equity
Total equity	4.8	6.2	3.1

	30 Jun 26	31 Dec 25	30 Jun 25	31 Dec 24
Non-current assets
Goodwill	–	5.7	–	2.1
Non-current assets	–	5.7	–	2.4
Current assets
Trade receivables	–	0.2	–	0.1
Cash	0.7	1.7	1.7	0.8
Current assets	–	1.9	–	0.8
Total assets	6.4	7.6	9.5	3.2
Current liabilities
Trade payables	–	0.5	–	0.1
Current liabilities	–	0.5	–	0.1
Non-current liabilities
Borrowings, non-current	–	0.1	–	–
Non-current liabilities	–	0.9	–	0.0
Total liabilities	–	1.4	–	0.1
Equity
Total equity	4.8	6.2	6.9	3.1

Read automatically from each results announcement. Check the source before relying on a figure.

Spotted an error in this income statement? Report it

Company filings. Not investment advice.